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Introduction {#sec1}
============

Our knowledge of metabolism is highly detailed, with fine mechanisms delineated at all biological levels and with large amounts of data being generated every day. However, even commonplace phenomena are still difficult to explain. Why does a middle-aged person gain weight much more easily than a younger person? What drives "middle-age spread?" Why is middle-age spread often followed by "old-age shrinkage?" Does the obvious change in weight defy the concept of weight stability? If not, what underlies weight stability? The existing answers to such questions are largely unclear or wrong, not because the molecular details are insufficient but because of the lack of physical laws that abstract away non-essentials. Such a law could be very powerful ([@bib66], [@bib67], [@bib55]).

We aimed to establish a law governing body weight dynamics. Note that the change in body weight is primarily due to the change in fat mass (FM) because the change in lean mass (LM) is much smaller, and weight stability is essentially related to fat mass homeostasis. To avoid proposing too simplistic a law, we studied metabolism at multiple biological levels from molecules to the organism ([@bib63], [@bib64], [@bib65], [@bib34]). In this paper, an ordinary differential equation (ODE) model was first developed to integrate the complexities. By using the model to analyze clinical data, we distilled a metabolic Ohm\'s law, which enables clear and quantifiable answers to the above questions. In particular, it reveals the parabolic trajectory of the weight change of an average sedentary adult ([Figure 1](#fig1){ref-type="fig"}E).Figure 1Body Mass Dynamics Governed by the Metabolic Ohm\'s Law(A) From middle-age spread to old-age shrinkage.(B) Electric circuit as an analogy to energy metabolism, where the lean (fat) tissue is analogous to a resistor (capacitor).(C) The functions LM(Age) and IR(Age) are presented by the green and blue curves, respectively. LM(Age) is a decreasing function ([Equation 13](#fd13){ref-type="disp-formula"}), analogous to the decreasing electric current in (B); IR(Age) is an increasing function ([Equation 14](#fd14){ref-type="disp-formula"}), analogous to the increasing electric resistance in (B).(D) FM(Age) was obtained by [Equation 7](#fd7){ref-type="disp-formula"} with LM(Age) and IR(Age) as input. Note that FM is analogous to the electric charge stored in the capacitor.(E) BW(Age) obtained by [Equation 8](#fd8){ref-type="disp-formula"}. The arrows indicate the stability of the trajectory.(F) Extended view of BW(Age) with age ranging from 40 to 42 years (to scale). The trajectory is so flat that the slow weight gain may not be noticed. The spikes indicate perturbations that demonstrate weight stability.(G) If peripheral insulin resistance remains constant (IR(Age) ≡ 1.60), fat is lost consistently.

Despite the clear pattern of weight change over the lifespan, on a shorter (but still long) timescale our weight appears to be very constant (as shown in [Figure 1](#fig1){ref-type="fig"}F, the weight is nearly flat for 2 years). Neumann noted constancy of his weight over more than a year, without conscious efforts to control food intake or expenditure ([@bib41]). The remarkable weight constancy was explained by Chow and Hall, who demonstrated the very slow dynamics of weight change, which effectively buffers fluctuations in bodily activity and food consumption ([@bib6]). However, constancy is not the same as stability. To be stable, the weight has to return to the original value after a transient perturbation to a new value. If the new value is maintained without returning to the old, then the weight is not stable, even if it is very constant. [Figure 1](#fig1){ref-type="fig"}F gives an example of weight stability. Following an upward deflection (the red arrow), the weight returns to the original value (the first green arrow). Following a downward deflection (the blue arrow), the weight also returns to the original value (the second green arrow). In recent decades, many perturbation experiments have been performed, which all demonstrated weight stability ([@bib57], [@bib42], [@bib53], [@bib38], [@bib52], [@bib32], [@bib33], [@bib31], [@bib49], [@bib51]). Although the weight value can be perturbed away by persistent overfeeding or underfeeding, it always returns to its original value once normal feeding is reinstated. Our weight is therefore truly stable.

To explain weight stability, Kennedy proposed the lipostatic set-point theory ([@bib27]), which has become a central tenet in metabolism: our body fat is under active regulation by the central nervous system (CNS). As a hormone secreted by adipocytes, leptin carries fat level information to the brain ([@bib73]). The signal is compared with a hypothetical "set-point" in the hypothalamus; and the difference acts as a feedback signal to modulate food intake and energy expenditure, thereby maintaining weight stability ([Figure S2](#mmc1){ref-type="supplementary-material"}). Despite being textbook knowledge ([@bib39]), the theory has serious problems: the nature of the neuronal set-point, including its existence, is unclear, and the roles played by leptin have been questioned ([@bib31], [@bib48], [@bib58], [@bib59], [@bib72]). See [Supplemental Information](#appsec1){ref-type="fn"} for more information. We believe the lipostatic theory is afflicted by two misconceptions. The first misconception is that weight change is a sign of destabilization, i.e., weight change and weight stability are mutually exclusive. The second misconception is that weight stability is regulated by the CNS through leptin signaling. The two misconceptions together provoked the concept of leptin resistance, a putative pathologic condition of the brain ([@bib21]), to explain the mysterious middle-age spread. Unfortunately, the existence of leptin resistance has not been verified. In contrast, perturbation experiments have demonstrated strong weight stability under all the tested conditions---weight destabilization simply does not exist.

In this paper, we found that weight value change and weight stability are independent. On the one hand, body weight changes naturally, and the trajectory of weight change is governed by a metabolic Ohm\'s law (which will be summarized later by [Equation 11](#fd11){ref-type="disp-formula"}). On the other hand, we found that the changing weight is actually stable, and the stability arises from each adipocyte\'s intrinsic self-tuning, which confers inertia on the body against deviating from the trajectory ([Figure 1](#fig1){ref-type="fig"}E, the gray arrows). Therefore, the weight is already stable even without regulation from the CNS. In summary, weight change and weight stability co-exist peacefully, just as the movement of a planet does not contradict the stability of the whole orbit. With this important decoupling, the main conundrums in the field would vanish when the fundamental assumptions of the present model are tested true. Middle-age spread is perhaps not a sign of destabilization but part of the natural trajectory of weight change, which conforms with all the perturbation experiments. Because weight stability is a peripheral autonomous and requires no central regulation, the applicability of the lipostatic theory, including the concept of leptin resistance, should be reconsidered.

If the brain has no intention to fix the fat storage, what is the biological function of the fat-leptin-hypothalamus axis? It might be simply to ensure a minimal fuel reserve for the lean tissues, as implied by the finding that leptin is physiologically important only at low concentrations and unimportant at normal to high concentrations ([@bib44]). In addition to fat, whose level is conveyed by leptin, the other energy substrates are also monitored, including plasma glucose (whose level is conveyed by insulin) and even food in the stomach (whose amount is conveyed by the hormone ghrelin) ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Integration of these signals allows the hypothalamus to holistically perceive the body\'s total energy status and to evaluate a suitable appetite so that the lean tissues\' energy demand can be met in a timely manner. A new paradigm, called leanocentrism, is formed.

[Figure S1](#mmc1){ref-type="supplementary-material"} presents a road map connecting different parts of this paper.

Results {#sec2}
=======

The Leanocentric Energy Balance {#sec2.1}
-------------------------------

Because the body\'s energy expenditure is essentially for lean tissues, we have$$\text{E}_{\text{intoLean}} = \text{TEE,}$$where E~intoLean~ is the daily energy entry into the lean tissues and TEE is the total energy expenditure per day ([Figure 2](#fig2){ref-type="fig"}A). The energy is ultimately from food intake (EI), which enters both lean and fat tissues ([@bib11]). The fat tissues also release free fatty acids (FFAs) to nourish the lean tissues. If the energy flowing into the fat tissues equals that flowing out, then the conventional energy balance is established:$$\text{E}_{\text{intoFat}} = \text{E}_{\text{outFat}},$$which is equivalent to (see [Figure 2](#fig2){ref-type="fig"}A)$$\text{EI} = \text{E}_{\text{intoLean}} = \text{TEE}$$Figure 2Leanocentric Energy Balance(A) Leanocentric energy balance (E~intoLean~ = TEE) is an overarching principle dominating body mass dynamics, including the conventional energy balance (E~intoFat~ = E~outFat~, or equivalently, EI = E~intoLean~ = TEE).(B) The insulin response curve *u*(INS). It is characterized by the threshold INS~on~. As INS~on~ increases, the response shifts to the right.(C) The distribution of myocytes and adipocytes over the lg(INS~on~) axis.(D) Explanation of middle-age spread. During aging, MD naturally shifts to the right, representing increased insulin resistance, which drags AD (being locked) in turn to the right, manifesting as a consistent increase in adipocyte size. (D1) explains a new mechanism of weight stability (fat mass homeostasis). AD can be perturbed to the right (left) by overfeeding (underfeeding). However, once normal feeding is reinstituted, it will gradually return to the locking point, indicated by the leftward (rightward) arrows.

In addition to Equations [2](#fd2){ref-type="disp-formula"} and [3](#fd3){ref-type="disp-formula"}, the conventional energy balance can also be expressed by$$\text{FM} \equiv \text{const.}$$

Note that conventional energy balance does not always hold. Energy imbalance (EI \> TEE or EI \< TEE) does occur occasionally.

We primarily consider a condition called *necessary feeding*; namely, EI is just sufficient for TEE. Note that this does not necessarily mean EI = TEE because under some conditions, EI has to be greater than TEE. For example, consider a man who has experienced prolonged starvation and is now allowed to eat freely. As a result of starvation, the adipocytes are very small and thus very insulin sensitive (see below); they thus preempt nutrient intake (E~intoFat~ overly large), making E~intoLean~ much smaller than EI. To fund the required TEE, EI must be far greater than TEE to make E~intoLean~ equal TEE. This "overeating" necessity lasts for some days, during which FM gradually increases and EI gradually decreases, until finally FM returns to the prestarvation value and EI approaches TEE, signifying restoration of the conventional energy balance. This adaptive change in EI according to the prescribed TEE is called necessary feeding. By using necessary feeding with a suitable value of TEE, overnutrition is ruled out, whereby the natural tendency of weight gain can be highlighted.

The ODE Model {#sec2.2}
-------------

We developed an ODE model ([Transparent Methods](#mmc1){ref-type="supplementary-material"}) to simulate the dynamics of plasma glucose (GLU), FFA, amino acids (AA), insulin (INS) concentrations, and the adipocyte masses *m*~*i*~ (*i* = 1, 2, ..., *N*~adipo~), where *N*~adipo~ is the number of in silico adipocytes ([Figures S4--S9](#mmc1){ref-type="supplementary-material"}). The model thus comprises (*N*~adipo~ + 4) ODEs and some algebraic equations. The value of *N*~adipo~ is chosen sufficiently small to make numerical simulations practical; thus, an *in silico* adipocyte represents a collection of many real adipocytes but not a single real adipocyte. In addition to the *N*~adipo~ in silico adipocytes, there are *N*~myo~ in silico myocytes (*j* = 1, 2, ..., *N*~myo~) in the model. Unlike in silico adipocytes, which are variables of the model, *in silico* myocytes are parameters of the model. Note that the subscripts *i* and *j* are used to number adipocytes and myocytes, respectively.

In the model, EI is in the form of meal ingestion, which prompts extensive changes in the concentration of the plasma nutrients and finally leads to their absorption by the body tissues, completing one meal cycle. By performing the simulation for three successive meal cycles, a day\'s system dynamics can be obtained. By performing the simulation for many days, a long-term system dynamics can be obtained.

For the parameter values of the model, most of them were obtained by fitting clinical data on plasma nutrient dynamics ([@bib45], [@bib46], [@bib4], [@bib5], [@bib24], [@bib61]). These canonical values, presented in [Table S1](#mmc1){ref-type="supplementary-material"}, were used by default in the simulations. That is, if a parameter\'s value is not mentioned for a simulation, then the canonical value was used. The two most important parameters, IR and TEE, being case dependent, were not assigned canonical values.

The validity of the computational model is suggested by the following: it is based on well-established principles; most of the canonical parameter values are taken from experimental measurements; and it can accurately predict the amount of weight change due to the change in TEE ([Figure S10](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc1){ref-type="supplementary-material"}).

Cell Insulin Responses and Threshold Distributions {#sec2.3}
--------------------------------------------------

Insulin stimulus elicits a variety of responses in a cell ([@bib47]), such as nutrient intake, suppression of proteolysis or lipolysis, and de novo lipogenesis. In this paper, insulin response refers specifically to nutrient intake. The response curve is denoted by *u*(INS) ([Figure 2](#fig2){ref-type="fig"}B), where *u* represents the cell\'s rate of nutrient intake and INS represents the plasma insulin concentration. The *N*~myo~ myocytes and *N*~adipo~ adipocytes compete for nutrients. That is, the growth of adipocyte *i* depends not only on its own insulin response *u*~*i*~(INS) but also on the myocytes\' insulin response: *u*~*j*~(INS) (*j* = 1, 2, ..., *N*~myo~), as well as the responses of other adipocytes.

Biochemical responses often follow a threshold mechanism ([@bib22]), which applies to insulin response ([@bib63], [@bib64], [@bib34]). In this paper, the insulin response *u*(INS) is a sigmoidal curve characterized by a response threshold INS~on~ ([Figure 2](#fig2){ref-type="fig"}B), which can be used to quantify the cell\'s insulin resistance. Indeed, the larger the threshold, the more difficult it is for the cell to respond, that is, the more resistant the cell is to insulin. In this paper, we used lg(INS~on~) to quantify a cell\'s insulin resistance because the biochemical dose response is conventionally plotted on the log scale, including the insulin dose response ([@bib4], [@bib2], [@bib7]). Each insulin-responsive cell has its own lg(INS~on~) value. By fitting the clinical data in ([@bib4]), we found that the cell lg(INS~on~) values form a roughly normal distribution ([@bib65]). The mean of the distribution, denoted by IR, is used to quantify the overall peripheral insulin resistance. Here, the myocyte and adipocyte distributions are considered separately, as a myocyte distribution (MD) and an adipocyte distribution (AD) ([Figure 2](#fig2){ref-type="fig"}C). Because muscle is the main insulin-responsive tissue, the mean of MD should be very close to IR. Therefore, the MD is simply denoted by (IR, *σ*~myo~), where *σ*~myo~ is the standard deviation. AD is denoted by (*μ*~adipo~, *σ*~adipo~).

A simulation result can be partly represented by the evolution of AD. In [Figure 3](#fig3){ref-type="fig"}A3, for example, the AD evolves as a part of the whole system\'s dynamics, starting from the initial blue distribution (arbitrarily given) and finally stabilizing at the yellow distribution. It will turn out that the location of the yellow distribution is largely determined by the MD (the brown distribution). In other words, the AD is finally locked by the MD, and the "blue to yellow" evolution can be regarded as the return of AD to the locking point. See also the rightward arrow in [Figure 2](#fig2){ref-type="fig"}D1. Similarly, if AD is initially perturbed to the right, then the subsequent evolution will be toward the left, indicated by the leftward arrow in [Figure 2](#fig2){ref-type="fig"}D1. Regardless of how AD is perturbed, it will finally return to the locking point, demonstrating weight stability. The above scenarios are under the condition that MD is fixed. In reality, MD shifts to the right very slowly (see below), which drags AD to the right very slowly ([Figures 2](#fig2){ref-type="fig"}D1--D3). Because adipocyte insulin resistance positively correlates with adipocyte size ([@bib54], [@bib15], [@bib23], [@bib71]), the right-shift of AD manifests as persistent weight gain, namely, middle-age spread.Figure 3Stabilization of Adipocytes(A1) The MD (1.80, *σ*~myo~), indicated by brown, was fixed. The initial AD (1.65, 0.05) is indicated by blue. The AD evolved and finally stabilized at lg(INS~on~) = 1.7947 (the yellow spike). (B1) Eleven FM(*t*), corresponding to 11 initial ADs as indicated by the 11 dots in the inset. (C1) The magnitude of meal supply *A* (see [Equation S13](#mmc1){ref-type="supplementary-material"}) as a function of time. Each color corresponds to the same color in B1. (A2) The MD (2.00, *σ*~myo~) was fixed. The initial AD (1.65, 0.05) evolved and finally stabilized at an elevated value lg(INS~on~) = 1.9681 (the yellow spike). (B2) Eleven FM(*t*), corresponding to IR = 2.00, and 11 initial ADs as indicated by the 11 dots in the inset. (D) Indication of the initial and final sizes of adipocytes. (A3) Same as A1 (IR = 1.80) but with randomized *u*~max~. That is, the maximum rate of nutrient intake *u*~max~ is different for different cells. (A4) Same as A3 except IR = 2.00.

Weight Is Stable in the Absence of Central Regulation {#sec2.4}
-----------------------------------------------------

To test weight stability using the ODE model, one can start with adipocytes of arbitrary masses, which would evolve as a part of the whole system\'s dynamics. If the masses finally stabilize, then weight stability is demonstrated. The following simulations reproduce weight stability. The stability is independent of lipostatic regulation because the model does not have such a component.

Consider a subject with TEE = 2,400 kcal/day and MD of (IR, *σ*~myo~) = (1.80, 0.35) ([Figure 3](#fig3){ref-type="fig"}A1, brown). Let the simulation start with an initial AD of (*μ*~adipo~, *σ*~adipo~) = (1.65, 0.05) ([Figure 3](#fig3){ref-type="fig"}A1, blue), corresponding to an initial FM of 13.4 kg. The AD shifted to the right and narrowed at the same time until all the adipocytes stabilized at the same lg(INS~on~) value of 1.7947 (the yellow spike) or at the same mass *m*~*i*~ = 0.00935 kg. Therefore, FM increased over time and finally stabilized at 0.00935 × *N*~adipo~ = 18.7 kg ([Figure 3](#fig3){ref-type="fig"}B1, the blue curve). Meanwhile, the food amount decreased over time and finally stabilized ([Figure 3](#fig3){ref-type="fig"}C1, the blue curve). This was an expected result under necessary feeding. The adipocytes were very small initially, signifying the body\'s energy deficit; thus, the initial "overeating" (EI \> TEE) was necessary.

The simulation was repeated ten times, each with a new initial AD. The 11 initial ADs are represented by the 11 dots of (*μ*~adipo~, *σ*~adipo~) in the inset of [Figure 3](#fig3){ref-type="fig"}B1. The colored dots correspond to the curves of the same color in [Figures 3](#fig3){ref-type="fig"}B1 and 3C1. The final FM was always 18.7 kg, corresponding to lg(INS~on~) = 1.7947 for every adipocyte (the yellow spike in [Figure 3](#fig3){ref-type="fig"}A1).

Peripheral Insulin Resistance Is a Determinant of Weight {#sec2.5}
--------------------------------------------------------

To learn muscles\' influence on FM, we started the simulation with the same 11 initial ADs but with MD shifted to the right (IR, *σ*~myo~) = (2.00, 0.35) ([Figure 3](#fig3){ref-type="fig"}A2, brown), which means that the muscle is more insulin resistant. The resultant functions FM(*t*) are presented in [Figure 3](#fig3){ref-type="fig"}B2. Compared with their IR = 1.80 counterparts, the primary difference was that the steady FM rose from 18.7 to 27.9. That is, every adipocyte\'s lg(INS~on~) increased from 1.7947 to 1.9681 ([Figure 3](#fig3){ref-type="fig"}A2, the yellow spike). Together with [Figures 3](#fig3){ref-type="fig"}A3 and 3A4 (see below), the results demonstrate that insulin resistance is a determinant of the weight value: AD is "locked" by MD. As MD moves to the right, AD moves concomitantly, and the adipocytes become larger (weight gain). This new mechanism is called the *leanocentric locking-point model*.

The model can explain the "environment-dictated adipocyte growth" phenomenon revealed by Ashwell et al., who transplanted adipocytes into recipient mice and found that the donor adipocytes always tune their size to that of the recipient adipocytes ([@bib1]). They concluded that the local environment of the transplantation site is important, but they did not know the determinant. Now, the puzzle is solved. As the yellow spikes in [Figures 3](#fig3){ref-type="fig"}A1 and 3A2 demonstrate, the final adipocyte sizes are determined by the recipient\'s peripheral insulin resistance, which is indeed an environmental factor around the graft. Therefore, the data of Ashwell et al. are consistent with the locking-point model, which in turn provides unique insights into the interpretation of the data.

Weight Stability Is a Cell-Autonomous Property of Adipocytes {#sec2.6}
------------------------------------------------------------

In the absence of lipostatic regulation, what causes FM homeostasis? A clue to the answer is that the adipocytes always grew to the same size eventually, no matter how different they had been to start with. This phenomenon suggests the adaptive growth of adipocytes: smaller (larger) ones grow faster (slower); thus, all the cells eventually reach the same size. Adaptive growth might be rooted in the positive correlation between an adipocyte\'s insulin resistance and its mass ([@bib54], [@bib15], [@bib23], [@bib71]). A large adipocyte is insulin resistant; thus, it usually absorbs too few nutrients to sustain itself, and the cell gradually shrinks. A small adipocyte is insulin sensitive; thus, it usually absorbs more nutrients than it actually needs, and the cell grows. Therefore, an adipocyte settles at a medium mass due to the self-tuning of insulin resistance.

The homogeneity of adipocytes, although a great indicator of self-tuning, is not quite realistic, because adipocytes should have certain heterogeneity in size ([@bib60]). The heterogeneity may originate from differential growth conditions. For example, cells in the vicinity of arteries are exposed to higher concentrations of nutrients and insulin and thus grow more than those in the vicinity of distal capillaries. The differential growth may counteract adaptivity and lead to a certain degree of heterogeneity. To test this idea, the maximal rate of nutrient intake *u*~max~, which had been a constant, was randomized with a normal distribution (*μ*~*u*max~, *σ*~*u*max~). With this change, AD evolved and finally stabilized at the yellow distribution ([Figures 3](#fig3){ref-type="fig"}A3 or 3A4 for IR = 1.80 or 2.00, respectively). The distributions were wide, corresponding to relatively heterogeneous adipocytes. The total FM was only slightly different from the case of constant *u*~max~ (17.86 versus 18.7 and 26.16 versus 27.9).

With heterogeneity now taken into account, FM homeostasis can be understood as the fixation of AD by MD. In [Figure 2](#fig2){ref-type="fig"}D1, the middle AD corresponds to the locked FM. It can be transiently perturbed to the right by overfeeding (the corresponding adipocytes become larger). However, once normal feeding is reinstituted, it will gradually return to the original position, as indicated by the leftward arrow. On the other hand, the middle AD can be transiently perturbed to the left by underfeeding (the corresponding adipocytes become smaller). However, once normal feeding is reinstituted, it will gradually return to the original position, as indicated by the rightward arrow. By adaptively tuning their insulin resistance, the adipocytes have acquired some inertia against deviation from the locking point. Because the CNS is not involved, weight stability is a cell-autonomous property of adipocytes.

The following simulations were all based on the randomized *u*~max~ with the normal distribution (*μ*~*u*max~, *σ*~*u*max~).

Middle-Age Spread Is Almost Irresistible {#sec2.7}
----------------------------------------

The simulations have demonstrated that insulin resistance promotes weight gain. The reverse, namely, weight gain promotes insulin resistance, has long been known ([@bib23], [@bib29], [@bib30]). As body fat increases, insulin signaling is more blunted by increased FFA levels, exacerbating insulin resistance. Therefore, weight gain and insulin resistance aggravate each other, forming a self-perpetuating circle (positive feedback loop). The loop does not define the direction of change: both automatic weight gain and automatic weight loss are possible consequences of the positive feedback. Indeed, fat loss enhances insulin sensitivity, and the enhanced insulin sensitivity reduces fat further; thus, the positive feedback can also lead to automatic weight loss. Why, then, is only weight gain automatic in reality? The reason might be that IR tends to increase during aging for many reasons, including aging-related increase of S-nitrosation in the insulin signaling pathway ([@bib50], [@bib43]). This natural tendency causes the direction of weight change ([Figure 2](#fig2){ref-type="fig"}D). Although measures such as exercises may reduce insulin resistance, the effects are temporary and die out rapidly. Middle-age spread is thus a natural manifestation of aging.

The aging-related IR aggravation is obviously a hypothesis of fundamental importance. The hypothesis is supported by some early studies. Ropelle et al. found that aging increases inducible nitric oxide synthase expression and S-nitrosation of major proteins involved in insulin signaling, thereby reducing insulin sensitivity in mouse skeletal muscle ([@bib50]). Fink et al. measured the degree of insulin resistance of 27 non-elderly (mean age 37 ± 2) and 17 elderly (mean age 69 ± 1) subjects, who were all healthy, non-obese, and leading active lives ([@bib18]). Although the difference in body adiposity was small between the non-elderly and elderly groups (body mass index \[BMI\]: 23 versus 24; relative body weight \[RBW\]: 0.94 versus 0.93), their difference in insulin resistance, quantified by glucose disposal rate, was striking (247 ± 12 versus 151 ± 17 mg×m^−2^×min^−1^). Having these evidences notwithstanding, the hypothesis needs to be further tested by more rigorous experiments. Indeed, the latter evidence can be questioned because BMI and RBW may not be good indicators of adiposity. The experiment can be re-performed in the future by using bioimpedance analysis (BIA) or dual energy X-ray absorptiometry (DXA) to obtain more accurate adiposity measurement.

The LM-IR-FM Equation {#sec2.8}
---------------------

In the ODE modeling, the parameters are fixed at their canonical values except TEE and IR, which do not have canonical values. Therefore, given a (TEE, IR) pair, the ODE model computes the corresponding steady FM. This raises the possibility of obtaining an algebraic relationship among the triad (TEE, IR, FM) by integrating the ODE model with sufficient clinical data. We actually replaced TEE with LM because the two are roughly proportional (see Equation (c) in [Figure 6](#fig6){ref-type="fig"}C and its explanation in the caption). LM is better suited to the equation because it is intrinsic to the body, as are IR and FM, whereas TEE is extrinsic. The equation is called the LM-IR-FM equation (LIFE).

To derive LIFE, we started from a rough estimation of IR. Because MD and AD are interlocked, IR should be close to the mean of AD ([Figure 2](#fig2){ref-type="fig"}C). Together with a further simplification that all the adipocytes are identical, we have$$\text{IR} \approx \lg\left( \text{INS}_{\text{on}} \right)_{i} = \lg\frac{m_{i}}{\xi} \approx \lg\frac{\text{FM}}{\xi \times N_{\text{adipo}}}.$$

Note that we have used [Equation S10](#mmc1){ref-type="supplementary-material"}, namely (INS~on~)~*i*~ = *m*~*i*~/*ξ*, which models the positive correlation between *m*~*i*~ and (INS~on~)~*i*~ ([@bib54], [@bib15], [@bib23], [@bib71]). Substituting *ξ* = 1.5×10^−4^ and *N*~adipo~ = 2000 ([Table S1](#mmc1){ref-type="supplementary-material"}) into the above equation, we obtain$$\text{IR} \approx 0.523 + \lg\left( \text{FM} \right)$$

To bring LM into the equation, note that LM should negatively correlate with IR. Intuitively, a more muscular man (LM larger) should be more insulin sensitive (IR smaller), thus the negative correlation. The underlying molecular mechanism is as follows: the more myocytes are in the body, the less ectopic fat deposition per myocyte and the more insulin sensitive the myocyte. To embody the negative correlation and conform with [Equation 5](#fd5){ref-type="disp-formula"}, LIFE was designed as$$\text{IR} = \gamma_{0} + \gamma_{1}\frac{\lg\left( \text{FM} \right)}{\text{LM} - \gamma_{2}}$$

To estimate the unknown parameters *γ*~0~, *γ*~1~, and *γ*~2~, we collected clinical data on 44 subjects from the literature ([Table S3](#mmc1){ref-type="supplementary-material"}). Each subject actually represents a group of people whose data were averaged in the original literature. By the estimation procedure described in [Transparent Methods](#mmc1){ref-type="supplementary-material"}, we obtained *γ*~0~ = 0.664, *γ*~1~ = 45.4, and *γ*~2~ = 0, with which [Equation 6](#fd6){ref-type="disp-formula"} can be presented as the straight line in [Figure 4](#fig4){ref-type="fig"}A. LIFE is also expressed in terms of the solution to FM:$$\text{FM} = \exp\left( \frac{\ln\ 10 \times \text{LM} \times \left( {\text{IR} - \gamma_{0}} \right)}{\gamma_{1}} \right),$$whereby the body weight is determined:$$\text{BW} = \text{LM} + \exp\left( \frac{\ln\ 10 \times \text{LM} \times \left( {\text{IR} - \gamma_{0}} \right)}{\gamma_{1}} \right)$$Figure 4Discovery of LIFE(A) A scatterplot of 44 subjects\' lg(FM)/LM (the *x* axis) and IR (the *y* axis). The latter was computed by the ODE model based on the subjects\' clinical data, especially TEE and FM. Regression analysis revealed a linear relationship between lg(FM)/LM and IR. The six subjects within the oval were outliers.(B) The obtained IR values of the 44 subjects.

LIFE Is a Better Health Indicator Than Body Mass Index {#sec2.9}
------------------------------------------------------

The 44 subjects in [Table S3](#mmc1){ref-type="supplementary-material"} were diverse, spanning from very thin (FM = 6.6 kg) to very fat (FM = 68.0 kg). Among them, 12 were athletes. They were classified according to BMI as normal weight, overweight, and obese. Their lg(FM)/LM and IR values are presented as the *x* and *y* coordinates, respectively, of the 44 dots in [Figure 4](#fig4){ref-type="fig"}A. There were six outliers whose data did not scatter around the regression line. In [Transparent Methods](#mmc1){ref-type="supplementary-material"}, we explain why they were outliers. Note that the six outliers were excluded from estimating *γ*~0~, *γ*~1~, and *γ*~2~.

For the 38 nonoutliers, those located toward the lower left should be healthier. The athletes\' IR values were near or below 1.5, whereas those of nonathletes generally ranged from 1.5 to 2.2. The four obese subjects were obviously unhealthy. The other weight categories were quite heterogeneous. The normal weight subjects scatter widely along the regression line, suggesting that normal weight does not correspond to normal health. For example, subject 18 (BMI = 24.9) might appear to be normal, but he or she was very insulin resistant, with an IR as high as those of the obese subjects. Overweight subjects are also widely scattered. Subject 39, although overweight, was actually healthy, with an IR value as small as those of some athletes. These results demonstrated that BMI is not a good health indicator. Interestingly, comparative analysis of FM measurement and BMI on the US 1999--2004 National Health and Nutrition Examination Survey (NHANES) data reached almost the same conclusion: a considerable proportion of subjects in the healthy BMI range 20--25 were found to have excess adiposity, whereas BMI \>30 reliably defines obesity regardless of age and sex ([@bib13]).

Therefore, LIFE ([Equation 6](#fd6){ref-type="disp-formula"}) provides a much better health indicator, namely, the body\'s peripheral insulin resistance computed from the body composition (LM and FM), which can be easily measured by methods such as BIA and dual-energy DXA.

LIFE Explains Forbes\' Data {#sec2.10}
---------------------------

LIFE can be expressed in terms of the solution to LM:$$\text{LM} = \frac{\gamma_{1}}{\text{IR} - \gamma_{0}}\lg\left( \text{FM} \right)$$

It is similar to an empirical formula relating FM to LM, namely, Forbes\' formula:$$\text{LM} = 23.9\lg\left( \text{FM} \right) + 14.2,$$which was discovered by the examination of FM and LM in six groups of subjects ([@bib19], [@bib20]). By presenting every group\'s average (FM, LM) as a dot in [Figure 5](#fig5){ref-type="fig"}A, Forbes found that these cross-sectional data can be well fitted by the dashed curve in [Figure 5](#fig5){ref-type="fig"}A, namely, the Forbes formula. The formula implies a positive correlation between LM and FM, which is unfortunately not applicable to the longitudinal body change of an ordinary middle-aged person, who is losing LM (sarcopenia) and gaining FM, resulting in a negative correlation between LM and FM. This puzzle is now resolved by [Equation 9](#fd9){ref-type="disp-formula"}, which contains in the denominator the critical factor IR, whose slow increase counteracts the increase in FM (which is in the numerator) and allows the slight decrease in LM, thus enabling the longitudinal negative correlation between FM and LM.Figure 5LIFE Explains Forbes' Data(A) Forbes\' cross-sectional data reveal that LM is a logarithmic function of FM. The dots represent clinical data collected by Forbes. The dashed curve is an empirical fitting by Forbes. The solid curve is a fitting by LIFE.(B) The bars represent IR values of the six subjects, estimated by substituting their (FM, LM) into [Equation 6](#fd6){ref-type="disp-formula"}.

LIFE fits with the six data best at IR = 2.0061 ([Figure 5](#fig5){ref-type="fig"}A, the red curve). This good but imperfect fitting is expected. With a fixed IR, LIFE describes a single person at a single time, which of course cannot fit perfectly with the data of six subjects whose IRs were all different. IR = 2.0061 should be some medium value among the six IRs, which is indeed the case ([Figure 5](#fig5){ref-type="fig"}B).

The Metabolic Ohm\'s Law {#sec2.11}
------------------------

[Equation 7](#fd7){ref-type="disp-formula"} can be converted into$$\left\{ \begin{matrix}
{V = I \times R} \\
{Q = e^{V}} \\
\end{matrix} \right.$$by the substitutions *I* = ln10×LM/*γ*~1~, *R* = IR -- *γ*~0~, *Q* = FM, and using a new variable *V*. [Equation 11](#fd11){ref-type="disp-formula"} is analogous to a resistor and capacitor connected in parallel, with *I*, *R*, *V*, and *Q* being the electric current, resistance, voltage, and charge, respectively ([Figure 1](#fig1){ref-type="fig"}B). The analogy is pertinent. The lean tissue, which primarily expends energy, is analogous to a power-dissipating resistor. The fat tissue, which primarily stores energy, is analogous to a power-storing capacitor. Quantitatively, FM measures the stored energy and is perfectly analogous to the stored electricity (*Q* = FM); the peripheral insulin resistance is naturally analogous to the electric resistance (*R* = IR−*γ*~0~); the analogy *I* = ln10×LM/*γ*~1~ is easy to understand because LM is proportional to TEE, which, as the energy current through the lean tissue, is perfectly analogous to the electric current through the resistor.

In [Equation 11](#fd11){ref-type="disp-formula"}, the first equation *V* = *I* × *R* is Ohm\'s law of the body\'s fuel metabolism; the second equation *Q* = *e*^*V*^ implies that the capacitor is not a regular one with a constant capacitance but a nonlinear one with a capacitance equaling the stored charge: *C* = d*Q*/d*V* = *Q*. In other words, the more the capacitor is charged, the larger its capacity of further charging. The self-perpetuating capacitor may originate from the self-perpetuating circle between weight gain and insulin resistance. It has already explained why individuals with higher body fat have higher fat gains. More importantly, it is easy to predict how much more the person with more fat will gain.

Ohm\'s Law Predicts How Much More the Person with More Body Fat Gains {#sec2.12}
---------------------------------------------------------------------

A middle-aged person gains weight much more easily than a younger person. As usual, the middle-aged person has more body fat (*Q*~*y*~ *\< Q*~*m*~; or *C*~*y*~ *\< C*~*m*~) and higher insulin resistance (*R*~*y*~ *\< R*~*m*~). Here, the subscripts *y* and *m* represent young and middle aged, respectively. Now let the two increase their regular EI by the same small amount *d*EI, i.e., *dI*~*y*~ = *dI*~*m*~ ([Figure 6](#fig6){ref-type="fig"}A1). The same condition leads to different outcomes due to two levels of differentiation. The resistance difference *R*~*y*~ *\< R*~*m*~ makes *dI*~*y*~ × *R*~*y*~ *\< dI*~*m*~ × *R*~*m*~, namely, *dV*~*y*~ *\< dV*~*m*~ ([Figure 6](#fig6){ref-type="fig"}A2). The capacitance difference *C*~*y*~ *\< C*~*m*~ further amplifies the effect *C*~*y*~*dV*~*y*~ \<\< *C*~*m*~*dV*~*m*~, namely, *dQ*~*y*~ \<\< *dQ*~*m*~ ([Figure 6](#fig6){ref-type="fig"}A3), indicating that the person with more body fat gains much more fat.Figure 6Metabolic Ohm's Law(A) A schematic diagram explaining why individuals with more body fat also gain more fat.(B) The fat gain *d*FM as a function of FM resulting from a regular increase in food amount *d*EI = 50 kcal/day, with PAL = 1.5.(C) Main equations of the metabolic-electric analogy, where REE represents "resting energy expenditure"; PAL represents "physical activity level," which is the ratio of TEE and REE (Equation a). PAL is usually between 1.4 and 1.7 for a sedentary adult. Equation b is taken from ([@bib8]), where *σ*~1~ = 23.9 kcal/(day×kg) and *σ*~2~ = 372 kcal/day. Equation c is the combination of Equations a and b.

The analytical expression of d*Q* was obtained in [Transparent Methods](#mmc1){ref-type="supplementary-material"}:$$d\text{FM} = \frac{\text{FM} \times \ln\text{FM} \times d\text{EI}}{\sigma_{1} \times \text{PAL} \times \text{LM}},$$where *σ*~1~ and PAL (physical activity level) are explained in the caption of [Figure 6](#fig6){ref-type="fig"}C. [Equation 12](#fd12){ref-type="disp-formula"} predicts how much more the person with more body fat gains. It shows that *d*FM scales as FM×lnFM, even faster than the linear scaling ([Figure 6](#fig6){ref-type="fig"}B). For example, a young person with 50 kg of LM and 10 kg of FM gains only 0.64 kg fat by eating 50 kcal more every day, whereas a middle-aged person with 50 kg of LM and 40 kg of FM gains 4.1 kg of fat, approximately 6.4-fold more than the young person. Importantly, the predictions are not difficult to test because the few parameters can be easily controlled or readily measured in clinical practice. This will help to validate and optimize Ohm\'s law.

Ohm\'s Law Governs Weight Change {#sec2.13}
--------------------------------

Middle-age spread does not usually continue into very old age. People in the last century mostly started to lose weight at approximately 55--60 years of age ([@bib68], [@bib56]). Assume that *R* is always increasing. Then, according to Ohm\'s law, the only way to slow down weight gain is to decrease *I* (i.e., the loss of LM, primarily due to sarcopenia), and the decrease has to accelerate to lead to weight loss. Indeed, it was discovered that sarcopenia is a progressive process involving the accelerated loss of muscle mass and function ([@bib9]). According to the Baltimore Longitudinal Study of Aging (BLSA) ([@bib37], [@bib17]), the annual rate of muscle loss is approximately 1%, 5%, and more than 10% by ages 40, 60, and 90 years, respectively ([Figure 1](#fig1){ref-type="fig"}C, the green dots). Note that the LM loss contributes to weight loss not only by itself but also by driving the reduction in FM ([Equation 7](#fd7){ref-type="disp-formula"}). Therefore, the transition from weight gain to weight loss will occur sooner or later, as long as the subject lives sufficiently long ([Figure 1](#fig1){ref-type="fig"}A).

To test this idea, we first obtained LM as a function of age ([Figure 1](#fig1){ref-type="fig"}C, the green curve):$$\text{LM}\left( \text{Age} \right) = \text{LM}_{30}\left\lbrack {1 - 0.00023\left( {\text{Age} - 30} \right)^{1.5}} \right\rbrack$$by fitting the BLSA sarcopenia data. According to the locking-point theory, peripheral insulin resistance increases consistently during aging; thus, IR(Age) is an increasing function. Here, we assumed that IR has an upper bound IR~max~; thus, the increase in IR slows down gradually, which can be readily modeled by a simple ODE *d*IR/*d*Age = (IR~max~ -- IR)/*T*~half~, where *T*~half~ is the half-maximum time starting from age 30 years. That is, *T*~half~ +30 is the age at which IR reaches (IR~max~ + IR~30~)/2, where IR~30~ is the IR at age 30 years. The simple ODE has an explicit solution:$$\text{IR}\left( \text{Age} \right) = \text{IR}_{\max} - \left( {\text{IR}_{\max} - \text{IR}_{30}} \right)\exp\left( \frac{30 - \text{Age}}{T_{\text{half}}} \right)$$

We let IR~30~ = 1.60 and IR~max~ = 2.10. This choice was inspired by [Figure 4](#fig4){ref-type="fig"}A, which shows that IR \< 1.50 and IR \> 2.20 are generally applicable to athletes and morbidly obese people, respectively; thus, the normal IR range should be close to (1.60, 2.10). By using *T*~half~ = 15 in [Equation 14](#fd14){ref-type="disp-formula"}, the function IR(Age) was drawn as the blue curve in [Figure 1](#fig1){ref-type="fig"}C. By Equations [7](#fd7){ref-type="disp-formula"} and [8](#fd8){ref-type="disp-formula"}, the functions FM(Age) and BW(Age) were obtained and presented in [Figures 1](#fig1){ref-type="fig"}D and 1E, respectively. The body weight peaks at age 61 years, which conforms well with the statistics ([@bib68], [@bib56]). To see how the results vary with *T*~half~, we repeated the computations with *T*~half~ ranging from 10 to 25 years and found that the age of peak weight ranges from 56 to 66 years, which are all reasonable ages of transition from weight gain to weight loss.

The Remarkable Energy Resistor {#sec2.14}
------------------------------

We have demonstrated the paramount importance of peripheral insulin resistance in energy metabolism. At the least, it governs both aspects of body mass dynamics: weight stability is achieved by the adipocytes\' self-tuning of their respective insulin resistance, and weight is dominated by the body\'s overall insulin resistance. Although the former (conferring stability) is certainly of merit, the biological significance of the latter is unclear.

We argue that the self-perpetuating circle of insulin resistance and weight gain is beneficial for long-term body protection. If our insulin resistance remained constant throughout, then our body fat would decline as sarcopenia progresses ([Figure 1](#fig1){ref-type="fig"}G, obtained with IR(Age) ≡ 1.6 and the LM(Age) expressed by [Equation 13](#fd13){ref-type="disp-formula"}); body weight would then decline even more. The diminishing body mass would make it increasingly difficult for elderly people to deal with emergent situations such as acute diseases, accidents, and calamities, especially in ancient times. The aggravation of insulin resistance allows automatic fat accumulation even under necessary feeding to address the potential dangers in old age. Therefore, moderate middle-age spread is not rooted in hypothalamus defects that cause central leptin resistance (as proposed by the lipostatic theory) but is a healthy natural process.

In addition to this long-term protection, peripheral insulin resistance offers immediate and indispensable life protection by sparing glucose for the brain while the plasma glucose level is low ([@bib40], [@bib65]). Peripheral insulin resistance, despite being the molecular mechanism underlying type 2 diabetes ([@bib26]), also plays critical roles in the body\'s fuel metabolism.

Discussion {#sec3}
==========

From Lipocentrism to Leanocentrism {#sec3.1}
----------------------------------

Body mass dynamics are traditionally considered from a lipocentric perspective, which emphasizes leptin-mediated central feedback regulation on body fat ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Besides the lipostatic set-point model, there are other lipocentric models, such as the "two intervention point" ([@bib25], [@bib58], [@bib59]) and "settling point" ([@bib69]), which are less popular and have various problems ([Supplemental Information](#appsec1){ref-type="fn"}). Despite dominance of the lipocentric view, the strong influence of LM on FM has long been recognized ([@bib14], [@bib35], [@bib12], [@bib3]). These works advocated the concept of LM homeostasis (protein-stasis), which works in parallel with FM homeostasis (lipostasis) to maintain the stability of both LM and FM, thus demonstrating a broader view ([@bib36]). However, neither of the two homeostatic mechanisms has been proven. Unlike the previous works that all focused on the *matter stored in* the tissues, this work focused on the *energy* *flowing through* the tissues, which led to the leanocentric locking-point model to compete with the existing models.

The Brain Only Has Limited Influence upon Body Weight {#sec3.2}
-----------------------------------------------------

What afflicts the previous models is the rather intuitive perception that weight stability and weight value change are mutually exclusive: the former (latter) is normal (abnormal). Here, Ohm\'s law has led to the surprising discovery that the two are independent and can thus be decoupled.

The weight value, as a steady state of the ODE model, is determined by the model parameters. [Table S2](#mmc1){ref-type="supplementary-material"} shows how FM changes with changes in TEE/EI, IR, *σ*~*u*max~, and *N*~adipo~. Because most of the parameters change randomly without a bias, the resultant FM change is negligible because the slow dynamics can effectively buffer fluctuations ([@bib6]). Interestingly, only TEE (analogous to *I*) and IR (analogous to *R*) change with a bias: the former (latter) generally decreases (increases), which generates a parabolic trajectory of weight change. Because TEE and IR are analogous to *I* and *R*, respectively, and their combined effect is quantitatively their product (*I* × *R*), Ohm\'s law is clearly in action. Note that both parameters change so slowly that our weight value appears to be constant for years ([Figure 1](#fig1){ref-type="fig"}F).

Weight stability, in this view, is due to adipocytes\' adaptive tuning of their insulin resistance, which confers some inertia against leaving the locking point; it is therefore a largely cell-autonomous property of adipocytes. Because leptin is physiologically effective only at low concentrations and unimportant at normal to high concentrations ([@bib44]), leptin signaling just effects to avoid an extremely low adiposity; thus, the central regulation does not intend to fix any weight value by conferring stability properties.

Insights on Thiazolidinedione Treatment {#sec3.3}
---------------------------------------

The above discussion on parameters helps to resolve a puzzle about thiazolidinedione (TZD), a class of insulin-sensitizing drugs. The drugs enhance insulin sensitivity; thus, according to the present theory, they should reduce body weight, but they are well known as weight boosters. This puzzle is actually easy to resolve considering that TZD is multifactorial: it not only enhances insulin sensitivity but also increases the number of adipocytes (*N*~adipo~) by promoting preadipocyte differentiation ([@bib62]). Because the increase in *N*~adipo~ causes weight gain ([Table S2](#mmc1){ref-type="supplementary-material"}), the concurrence of insulin sensitization and weight gain can be explained by the locking-point model provided that the increase in the number of adipocytes more than balances the decrease in the size of the adipocytes.

Remarkably, starting from the leanocentric principle, one can correctly predict the scenarios induced by TZD. In other words, TZD-induced adipose tissue remodeling, particularly preadipocyte differentiation, is largely an inevitable consequence of the locking-point model. [Figure 7](#fig7){ref-type="fig"}A indicates the original MD and AD. After the TZD treatment, the MD moves leftward (the blue arrow in [Figure 7](#fig7){ref-type="fig"}B) due to insulin sensitization. According to the locking-point model, the AD, being locked, also shifts to the left (the green arrow), and the adipocytes become smaller. Now that the adipocytes are shrinking, why does the weight increase instead? There must be massive numbers of new adipocytes generated (preadipocyte differentiation). The new adipocytes grow increasingly large (the red arrow); the original adipocytes become increasingly small (the green arrow); and finally, the two groups become indistinguishable. Due to the left-shifted MD, the final adipocytes are generally smaller than those before TZD treatment. Therefore, the increase in *N*~adipo~ has to be large to cause weight gain; otherwise, the weight may still decrease. These predictions conform well with experimental observations ([@bib10], [@bib62], [@bib28]). [@bib10] found that TZD treatment led to "the shrinkage and/or disappearance of existing mature adipocytes," which corresponds to the green arrow in [Figure 7](#fig7){ref-type="fig"}B. On the other hand, the study by [@bib62] indicated that "TZDs roughly double the number of adipocytes formed during treatment, compared with controls"; [@bib16] pointed out that "TZD-associated weight gain has been mostly attributed to the formation of new fat cells."Figure 7Scenarios Induced by TZD Treatment(A) MD and AD before TZD treatment.(B) After TZD treatment, MD moves to the left (the blue arrow), showing the insulin sensitization effect of TZD. The original adipocytes also move to the left (the green arrow) to satisfy the leanocentric principle. However, new adipocytes must be generated to account for the increased weight (the red arrow).

Ignoring the leanocentric principle may lead to wrong conclusions. For example, a more direct and intuitive possibility is that the original adipocytes, by absorbing more nutrients in response to TZDs, can already explain the weight gain. TZDs, through engaging PPAR-*γ*, upregulate the expression of glucose transporter 4 (GLUT4) on the plasma membrane of adipocytes ([@bib70]). This would give the adipocytes an advantage in competing with the muscles and thus favor the gain of weight. This view may well be wrong for the following reasons. First, the TZDs enhance the body\'s overall insulin sensitivity; thus, MD must shift to the left (the blue arrow in [Figure 7](#fig7){ref-type="fig"}B). That is, myocyte nutrient intake is also enhanced, which compromises adipocyte improvement. Second, even if an adipocyte has managed to grow larger, its nutrient intake capacity immediately decreases due to the increase in its individual insulin resistance ([Equation S10](#mmc1){ref-type="supplementary-material"}), which cancels the effect of the TZDs. Taken together, TZDs are unlikely to promote the growth of the original adipocytes. Indeed, experimental observations have demonstrated the shrinkage but not growth of the existing mature adipocytes ([@bib10]). In summary, leanocentrism can adequately explain why a likely scenario (the growth of the original adipocytes) cannot actually happen. This, together with the correct prediction of what is actually happening (the generation of new adipocytes), demonstrates the overarching role played by leanocentrism.

Furthermore, we predict that TZD would increase appetite during the early stage of its administration. In the early stage, the newly generated adipocytes are very small and thus very insulin sensitive; they thus absorb large amounts of nutrients, which necessitates large amounts of food intake ("overfeeding"). As the adipocytes grow larger, the "overfeeding" becomes lesser necessary, and the appetite would gradually decrease, approaching the pre-treatment level. This predication can be tested through *ad libitum* feeding of a mouse under continuous TZD treatment. We expect that the mouse develop hyperphagia in the early but not late days of the TZD treatment.

Limitations of the Model {#sec3.4}
------------------------

Although the leanocentric locking-point model has considerable explanation and prediction power, its fundamental principles have not yet been firmly established. First, the leanocentric energy balance ([Equation 1](#fd1){ref-type="disp-formula"}) depends on the assumption that LM commands energy intake, which, however, has no direct experimental support. Second, the aging-related IR aggravation is critical to explain middle-age spread and is thus the key to demonstrate the merits of the present theory over the lipostatic theory. Although having some supportive data, the assumption needs further testing by more rigorous experiments.

The ODE model was designed to simulate a sedentary adult\'s FM change during aging. It has to be modified before being used in the other circumstances. To simulate the athletes\' body energy metabolism, for example, at least some parameter values need to be changed because the canonical parameter values used by the model were estimated from data on sedentary people. Our theory can explain TZD-induced adipose tissue remodeling, but the validation of the explanation necessitates an extension of the ODE model by at least including new adipocyte recruitment. The extended model can then be used to validate our explanation by fitting its simulation runs with some TZD experimental or clinical data.

Leanocentrism is valid under most conditions but may become irrelevant under some extreme conditions, such as the leptin deficiency in ob/ob mice, which causes them to constantly overeat. The mice rapidly develop obesity. As their adipocytes become increasingly large, the AD consistently moves toward the right with no regard to the position of the MD. On the other hand, the ever-increasing muscle fat deposition continuously exacerbates insulin resistance and drives the MD toward the right. Because now AD commands the movement of MD, it is clearly a case of adipocentrism instead of leanocentrism. Therefore, leanocentrism is not a tenet, although it is applicable to most circumstances.

Resource Availability {#sec3.5}
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